Organic Base XOI Formulations for Solubility and Dissolution
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Xanthine oxidase inhibitors like allopurinol and oxypurinol are poorly soluble and poorly bioavailable, leading to challenges in effectively treating conditions associated with hyperuricemia, such as gout and hypertension, and they often cause adverse side effects.
Innovation Solution
Formulations of xanthine oxidase inhibitors with organic bases, particularly basic amino acids, enhance solubility and bioavailability, providing liquid compositions that improve dissolution rates and reduce side effects.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Quantity of substance
If xanthine oxidase inhibitors (allopurinol, oxypurinol) are administered in traditional tablet form, then the formulation is simple and easy to manufacture, but the solubility and bioavailability are poor
Solution Approach 1:
The patent introduces organic bases (such as arginine, lysine, or other basic compounds) as intermediary substances that mediate between the xanthine oxidase inhibitor and the body's absorption mechanisms. These organic bases form complexes with the poorly soluble XOI, enhancing solubility and bioavailability without requiring complete reformulation of the drug substance itself.
Solution Approach 2:
The patent changes the chemical parameters of the XOI formulation by combining it with organic bases having specific pKa values and molecular structures. This parameter change transforms the solubility and absorption characteristics of the drug, converting it from a poorly soluble state to a more bioavailable form while maintaining therapeutic activity.
2Speed
If xanthine oxidase inhibitors are administered in traditional tablet form, then the manufacturing process is simple, but the dissolution rate is slow
Solution Approach 1:
Organic bases serve as intermediary agents that facilitate faster dissolution of the xanthine oxidase inhibitor by forming soluble complexes that dissolve more rapidly in gastrointestinal fluids compared to the parent drug alone, thereby increasing the dissolution rate without complicating the manufacturing process excessively.
Solution Approach 2:
The patent creates composite material systems where the xanthine oxidase inhibitor is combined with organic bases to form new formulation entities. These composite formulations exhibit enhanced dissolution rates due to the synergistic properties of the combined materials, while the manufacturing process remains relatively straightforward using conventional mixing and formulation techniques.
3Reliability
If xanthine oxidase inhibitors are administered at effective doses, then therapeutic effect is achieved, but adverse side effects occur
Solution Approach 1:
The organic base acts as a protective intermediary that modifies the pharmacological interaction between the xanthine oxidase inhibitor and the body. This intermediary complex reduces harmful effects such as gastrointestinal irritation and other adverse reactions while maintaining the therapeutic inhibition of xanthine oxidase, thereby improving the safety profile of the drug.
Solution Approach 2:
By changing the chemical parameters of the drug through complex formation with organic bases, the patent modifies the pharmacokinetic profile of the xanthine oxidase inhibitor. This parameter change results in improved therapeutic efficacy at lower effective doses while reducing the incidence and severity of adverse side effects through altered absorption and distribution characteristics.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The formulations increase solubility and bioavailability of xanthine oxidase inhibitors, leading to improved therapeutic effects, including decreased serum uric acid levels and increased nitric oxide availability, while minimizing side effects.
Implementation Method 1
a pharmaceutical composition comprising a xanthine oxidase inhibitor and organic base that enhances or effects solubilisation of the xanthine oxidase inhibitor
Implementation Method 2
increased equilibrium solubility, increased dissolution rate and solubility of XOI and more specifically of oxypurinol using organic and or basic organic molecules
Data Source
AI summary
Disclosed herein are methods and compositions for involving a xanthine oxidase inhibitor that has enhanced solubility. The compositions described herein include a xanthine oxidase inhibitor combined with an organic base. The compositions can be used to treat a disease or medical condition that involves elevated uric acid levels.